Nick Kontorinis ESA-SRB-ANZOS 2025 in conjunction with ENSA

Abstracts this author is presenting:

• Direct effects of survodutide on liver endpoints beyond weight loss: insights from a phase 2 trial of the glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide in people with metabolic dysfunction-associated steatohepatitis and fibrosis — ANZOS Concurrent 16 Incretin Issues - Practical discussions for prescribing clinicians and others wanting answers